\n

Indication:? \nApremilast, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: \n \n

\n \n

\n
• Adult patients with active psoriatic arthritis
\n
• Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
\n

\n

Dosage & Administration: \nDosage in Psoriatic Arthritis and Psoriasis \n \nThe recommended initial dosage titration of Apremilast from Day 1 to Day 5 is shown in Table 1. Following the 5-day titration, the recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6. This titration is intended to reduce the

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	AM	PM
Day 1	10 mg	-
Day 2	10 mg	10 mg
Day 3	10 mg	20 mg
Day 4	20 mg	20 mg
Day 5	20 mg	30 mg
Day 6 & thereafter	30 mg	30 mg

\ngastrointestinal symptoms associated with initial therapy. \n \nApremilast can be administered without regard to meals. Do not crush, split, or chew the tablets. \n \nTable 1: Dosage Titration Schedule \n \nDosage Adjustment in Patients with Severe Renal Impairment \n \nApremilast dosage should be reduced to 30 mg once daily in patients with severe renal impairment (creatinine clearance (CLcr) of less than 30 mL per minute estimated by the Cockcroft?Gault equation). \n \nFor initial dosage titration in this group, it is recommended that Apremilast be titrated using only the AM schedule listed in Table 1 and the PM doses be skipped. \n

Preparation:? \nOtelast^??10: Each box contains 20 tablets in alu-alu blister pack. \nOtelast^? 30: Each box contains 20 tablets in alu-alu blister pack.

\n \n